The manager of two cannabis-centric Canadian exchange-traded funds (ETFs) added 18 new cannabis stocks into the two indexes.
On Wednesday (September 26), Horizons ETFs Management completed a quarterly rebalance of the holdings in its two cannabis ETFs— the Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ) and the Horizons Emerging Marijuana Growers Index ETF (NEO:HMJR).
The Horizons Marijuana Life Sciences Index ETF now holds close to 50 cannabis stocks, while the other index carries 38 stocks.
Cannabis ETFs offer investors a chance to gain a measured exposure into the sector through variety of companies as opposed to picking individual stocks. With the growth of the overall cannabis sector, these offerings have increased as well.
Steve Hawkins, president and CEO of Horizons ETFs, said these rebalances come at a “significant time” for the industry as legalization of recreational cannabis in Canada is scheduled for October 17.
“With recreational sales starting soon, investors will get a better idea of what companies are poised to become leaders in the recreational cannabis space and are able to generate real sales,” Hawkins said in the company’s press release.
The ETF management company has made HMMJ its premier offering while its second cannabis ETF, which launched in February, is solely focussed on smaller market cap North American companies.
“As they grow, these budding marijuana companies have the opportunity to graduate into HMMJ’s index, allowing investors to participate in the full growth cycle of these businesses through our two marijuana based ETFs,” Hawkins explained.
Here’s a list of the stocks HMJR added:
- Alefia Health (TSXV:ALEF)
- Ascent Industries (CSE:ASNT)
- Choom Holdings (CSE:CHOO)
- Chemesis International (CSE:CSI)
- James E. Wagner Cultivation (TSXV:JWCA)
- Khiron Life Sciences (TSXV:KHRN)
- Maple Leaf Green World (AQN:MGW)
- 48North Cannabis (TSXV:NRTH)
- Planet 13 Holdings (CSE:PLTH)
- Sunniva (CSE:SNN)
- Sproutly Canada (CSE:SPR)
- Wildflower Brands (CSE:SUN)
The rise of HMMJ is related to the growth of the holdings it has. The index’s top weighed holdings as of Tuesday (September 25) were: Aurora Cannabis (TSX:ACB), Canopy Growth (NYSE:CGC,TSX:WEED), Aphria (TSX:APH) and GW Pharmaceuticals (NASDAQ:GWPH).
The three Canadian producers have a combined market cap of over C$32 billion, while the pharmaceutical company has raised its profile after obtaining a critical approval in the US for a cannabidiol-based (CBD) medicine.
Here’s all the stocks added to the holdings of HMMJ:
- Alefia Health
- Choom Holdings
- Eve & Co. (TSXV:EVE)
- GTEC Holdings (TSXV:GTEC)
- FSD Pharma (CSE:HUGE)
- James E. Wagner Cultivation
- Namaste Technologies (TSXV:N)
- INDIVA (TSXV:NDVA)
- Tilray (NASDAQ:TLRY)
Tilray’s inclusion should add even more value to the index as the Canadian company has enjoyed a substantial rush in the public markets for the past two months.
These scheduled quarterly rebalances for the two ETFs offer investors a chance to see which companies have gained the attention from the market and a chance to gain exposure into emerging cannabis industry.
Both HMMJ and HMJR have taken the ups and downs of the cannabis sector volatility but have seen gains so far in 2018. HMMJ raised in value 16.65 percent, over a year-to-date period. As the markets closed on Wednesday’s trading session, HMMJ reached a price of C$24.35.
Since its launch, HMJR has seen an uptick in value thanks to the growth of its holdings. Despite trading on the lesser known Aequitas NEO Exchange, as of 2:30 p.m. EST on Wednesday the holds a price of C$9.27. HMJR has seen a 52-week high price of C$10.48.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Editor’s Note: The headline of this article was changed since it incorrectly stated 17 cannabis stocks were added to the Horizons ETFs.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: Ascent Industries, Chemisis International, James E. Wagner Cultivation, Khiron Life Sciences, Maple Leaf Green World, GTEC Holdings, FSD Pharma and INDIVA are clients of the Investing News Network. This article is not paid-for content.
Meanwhile, two longstanding cannabis partners ended their relationship.
Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development
Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.
The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.
With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.
DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.